120 min达雷妥尤单抗快速输注的观察及护理  

Observation and nursing care of 120 min rapid infusion of daretuumab

作　　者：郝蕊 董妍妍 胥葆楠 王雯 HAO Rui;DONG Yanyan;XU Baonan;WANG Wen(Hospital of Hematology,Chinese Academy of Medical Sciences(Institute of Hematology,Chinese Academy of Medical Sciences)/National Key Laboratory of Blood and Health/National Center for Clinical Medical Research of Hematological Diseases/Haihe Laboratory of Cell Ecology,Tianjin 300020 China;Tianjin Institute of Medical Health)

机构地区：[1]中国医学科学院血液病医院(中国医学科学院血液学研究所)/血液与健康全国重点实验室/国家血液系统疾病临床医学研究中心/细胞生态海河实验室,天津300020 [2]天津医学健康研究院

出　　处：《护理研究》2025年第5期838-842,共5页Chinese Nursing Research

摘　　要：目的:探讨达雷妥尤单抗快速输注的安全性及耐受性,为快速输注方案在各中心治疗和日间病房应用的可行性及临床护理提供支持。方法:采用达雷妥尤单抗快速输注法,120 min滴毕:液体总量为500 mL,初始输注速率为200 mL/h,前30 min输入液体总量的20%(100 mL);后90 min调整输注速率至270 mL/h,输入剩余80%(400 mL)液体。心电监护持续监测生命体征并观察记录。结果:观察149例病人,共1 362例次接受达雷妥尤单抗治疗,仅有11例次(0.81%)病人出现1级或2级输液相关不良反应,没有病人发生2级以上的输液相关反应。结论:对于首次和第2次标准输注未出现2级以上的输液相关反应病人,采用120 min达雷妥尤单抗快速输注法可行,可明显缩短输注时间,减少病人住院时间和费用,提高病人舒适度及便利性,减轻护士的工作量。Objective:To investigate the safety and tolerability of rapid infusion of daratumumab and to provide support for the feasibility of rapid infusion protocols in chemotherapy and day hospital settings and in clinical nursing.Methods:Rapid infusion of daratumumab was administered(completed within 120 minutes:total infusion volume of 500 mL),with an initial infusion rate of 200 mL/h for the first 30 minutes(20%of the total volume,100 mL);the infusion rate was adjusted to 270 mL/h for the remaining 90 minutes to administer the remaining 80%(400 mL)of the fluid.Continuous electrocardiographic monitoring was used to observe and record vital signs.Results:Among the 149 patients observed,who received a total of 1362 daratumumab treatments,only 11 patients(0.81%)resulted in grade 1 or 2 infusion⁃related reactions(IRR),and no patients experienced grade 3 or higher IRRs.Conclusions:For patients who did not experience grade 3 or higher IRR during their first and second standard infusions,the 120-minute rapid infusion method of daratumumab is feasible.It significantly shortens infusion time,reduces patient hospital stays and costs,enhances patient comfort and convenience,and alleviates nurses′workload.

关 键 词：多发性骨髓瘤 达雷妥尤单抗 快速输注法 输液相关反应 护理 满意度 

分 类 号：R473.73[医药卫生—护理学]